Sewing: "Deutsche Bank's third quarter started well"

Sewing: "Deutsche Bank's third quarter started well"

Deutsche Bank's third quarter has begun on a positive note, with the investment bank upgrading its recommendation for Sanofi shares from "hold" to "buy." This upgrade, driven by optimism over the potential of Sanofi's new treatment for atopic dermatitis, amlitelimab, has led to a significant increase in the company's stock price. The analysts at Deutsche Bank have raised their target price for Sanofi shares to €110, indicating a 22% upside potential [1].

The optimism surrounding amlitelimab stems from its potential to replace Dupixent, Sanofi's flagship drug, which accounts for nearly half of its pharmaceutical revenues. However, the patent for Dupixent is set to expire in 2031, creating a significant risk for the company's stock market valuation [2]. Deutsche Bank believes that amlitelimab, with its imminent Phase 3 data in atopic dermatitis, could take over from Dupixent, as this condition represents more than 70% of Dupixent's current revenues. The analysts have raised their price target for Sanofi shares to €110, a 22% increase from their previous target, highlighting the potential for amlitelimab to significantly boost the company's revenues.

The upgrade from Deutsche Bank reflects growing optimism among investors about Sanofi's ability to diversify its revenue streams and mitigate the risks associated with the expiration of its flagship drug's patent. The upcoming Phase 3 results for amlitelimab will be closely watched by investors, as they could significantly impact the company's future prospects.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3UP06J:0-db-upgrades-sanofi-to-buy-on-eczema-drug-potential/
[2] https://www.marketscreener.com/news/sanofi-stock-rises-on-deutsche-bank-upgrade-ce7c50d3dd88f721